Mutations of OCRL1 are associated with both the oculocerebrorenal syndrome Lowe, a multi-systemic and Dent-2 disease, a renal tubulopathy. We have identified a mutation in 130 Lowe syndrome families and 6 affected by Dent-2 disease with 51 of these mutations being novel. No founding effect was evidenced for recurrent mutations. Two mutations initially reported as causing Dent-2 disease were identified in patients, including two brothers, presenting with Lowe syndrome thus extending the clinical variability of OCRL1 mutations. mRNA levels, protein content and PiP 2 -ase activities were analyzed in patient's fibroblasts. Although mRNA levels were normal in cells harbouring a missense mutation, the OCRL1 content was markedly lowered suggesting that enzymatic deficiency resulted mainly from protein degradation rather than a catalytic inactivation as usually reported. Analysis of a splicing mutation that led to the elimination of the initiation codon evidenced the presence of shortened forms of OCRL1 that might result from the use of alternative initiation codons. The specific mapping of the frameshift and nonsense mutations, exclusively identified in exons 1-7 and exons 8-23 respectively for Dent disease and Lowe syndrome together with the possible use of alternative initiation codons might be related to their clinical expression i.e. Lowe syndrome or Dent-2 disease.
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L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt età la diffusion de documents scientifiques de niveau recherche, publiés ou non, emanant desétablissements d'enseignement et de recherche français ouétrangers, des laboratoires publics ou privés. The oculocerebrorenal syndrome of Lowe (OCRL [MIM#309000]) is a rare X-linked multisystem disorder presenting with major abnormalities in the eyes, the kidneys and the central nervous system [Lowe et al., 1952; Loi, 2006] . OCRL is a rare disease with a prevalence estimated between 1 and 2 boys per million people. Ocular abnormalities include a constant prenatal development of cataracts and frequent associated signs such as glaucoma, microphthalmos, decreased visual acuity and corneal keloid formation. Neonatal hypotonia, intellectual impairment and areflexia are also cardinal features. The majority of patients have a cognitive delay and behavioural troubles including temper tantrums and aggressiveness are frequently noted. Brain magnetic resonance imaging (MRI) may show periventricular cystic lesions [Schneider et al., 2001; Loi, 2006] . Fanconi syndrome, a generalized impairment of the proximal tubular cells functions, is a major feature.
Onset of the tubular dysfunction can vary between patients and the severity tends to worsen with age. Low molecular weight proteinuria (LWMP) is invariably present and aminoaciduria, hypercalciuria and bicarbonaturia are frequently included. Progressive glomerular dysfunction leads usually to renal failure. Skeletal muscle abnormalities may develop as secondary consequences of hypotonia or renal dysfunction. Nontender joint swelling and subcutaneous nodules are also frequently described in affected patients and may reflect a primary abnormality of connective tissue growth. Lowe syndrome results from mutations of the OCRL1 gene (MIM #300535) that encodes a phosphatidyl inositol 4,5 Dent's disease (Dent-1, MIM#300009), is a X-linked proximal renal tubulopathy, characterized by LWMP, hypercalciuria and progressive renal insufficiency. In addition, other features of proximal tubular dysfunction such as glycosuria, aminoaciduria, phosphaturia, uricosuria or complete Fanconi syndrome may also be present [Dent and Friedman, 1964; Thakker, 2000] . Except for rickets noted in some patients; no extra-renal manifestations of the disease have been reported.
Mutations in the CLCN5 gene (MIM #300008) encoding the renal voltagegated chloride channel CLC-5 have been reported in 60% of patients with Dent's disease [Lloyd et al., 1996 , Hoopes et al., 2004 . ClC-5 is mainly localized in subapical endosomes of epithelial kidney cells and contributes to the acidification of intra-endosomal compartments and participates in membrane recycling in the proximal tubule [Devuyst et al., 1999; Piwon et al., 2000] . A recent study showed that mutations in the OCRL1 Nevertheless, DD-2 patients harbouring an OCRL1 mutation displayed comparable decrease in PI(4,5)P2ase activity and OCRL1 content to those reported for patients affected by Lowe syndrome [Hoopes et al., 2005;  this study].
OCRL1
OCRL1 is a type II inositol polyphosphate 5-phosphatase that participates into the Lowe, 2005] . OCRL1 has been originally localized to the Trans-Golgi Network and to lysosomes [Olivos-Glander et al., 1995; Dressman et al., 2000; Ungewickell et al., 2004] and more recently to endosomes [Choudury et al., 2005; Hyvola et al., 2006; Erdmann et al., 2007] . Abnormalities in the actin cytoskeleton have been demonstrated in Lowe fibroblasts Nussbaum, 2002] and OCRL1 was recently proposed to play a role in regulating membrane trafficking and actin dynamics [Lowe, 2005; Faucherre et al, 2005] .
The OCRL1 gene spans 52278 bp on chromosome Xq24.26 [ENSG00000122126] and contains 24 exons with exon 18a as an alternatively spliced exon mostly expressed in brain [Attree et al., 1992; Nussbaum et al., 1997 ]. The ATG start codon was initially assigned to exon 2 [Attree et al, 1992] , however recent reports mapped the initiation codon in exon 1 [Hyvola et al., 2006; Erdmann et al, 2007; Mao et al., 2009] . Accordingly the 5156 bp cDNA (NM_000276) encodes a protein monomer of 901 amino-acids (MW = 103 226 kDa).
This paper reports 51 novel mutations of the OCRL1 gene associated either with Lowe syndrome or Dent-2. Correlations between the mutations and their expression at the mRNA, functional and protein levels will be discussed in regard to their clinical expression. Based on these data, putative mechanisms to explain how mutations of the OCRL1 protein express as heterogeneous clinical entities will be discussed. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
MATERIAL AND METHODS

Patients and samples
Mutation detection
Genomic DNA was isolated using standard procedures. The 24 exons of the OCRL1 gene were amplified from genomic DNA as described previously [Monnier et al., 2000] . For mutational analysis, PCR-amplified DNA products were subjected to direct automated sequencing on an ABI 3130 DNA Analyser (Life Technologies, Carlsbad, CA, USA).
Alternatively RNA was extracted from 2-5 10 6 fibroblast cells using the Trizol reagent (Life Technologies, Carlsbad, CA, USA). RNA was dissolved in 50 µl of RNAsefree water. Reverse transcription was performed by using 0.2 mg of total RNA at 48°c for 60 minutes with 50 U of Expand Reverse Transcriptase (Roche, Basel, Switzerland) and in the presence of oligo-dT and the following specific primer (5'-AACTTTGGCTTGGCAATATAAGTC). The resulting cDNA was then amplified and sequenced as previously described. 24 Mutations responsible for aberrant sized transcripts were characterized by direct sequencing of the corresponding exon and intron-exon junctions.
Mutation assignment was based on the cDNA sequence (Genbank # NM_000276) using the first coding ATG of exon 1 as initiation codon according to international guidelines for description of sequences variants (http://www.hgvs.org/mutnomen). This resulted in an in frame addition of 51 nucleotides at the 5' end of the cDNA and of 17 amino acids at the N terminal end of the protein in comparison with the initial nomenclature [Attree et al., 1992] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 , 2010] .
Quantitative transcript analysis
Quantitative PCR was performed using 100 ng of cDNA in a final volume of 25 µl and specific primers for the OCRL1 gene (F-5'-CGAGCTGTATCAGCGATGTC; R-5'-GGAGGCCTCAGGAGAAGACT) and the GAPDH gene used as control (F-5'-CATCAAGAAGGTGGTGAAGC; R-5'-GAGCTTGACAAAGTGGTCGT). The OCRL1 primers allowed the amplification of a 197 bp fragment spanning exon 21 to 23. Duplicated samples were PCR were run on a iQ Cycler apparatus in presence of the iQ SYBR Green Supermix containing 500 nM primers (Biorad, Hercules, CA, USA).
Enzymatic assay for PI(4,5)P 2 phosphatase activity
Activity was assayed as described previously on cell extracts prepared by freezethawing of fibroblasts obtained from affected and non affected patients except that each assay included 50 µg of fibroblast protein and that quantification was performed by direct analysis of the TLC plates using a Beta Imager 2000 (Biospace, Paris, France) [Suchy et al., 1995; Satre et al., 1999] .
Western blot analysis
For western blot analysis, aliquots of cell extracts (25 µg of protein) were resolved by an 8% SDS-polyacrylamide gel electrophoresis and electro-blotted onto Immobilon P transfer F o r P e e r R e v i e w 8 membrane (Millipore, Billerica, MA, USA). OCRL1 was revealed using polyclonal antibodies raised in rabbit against the N-terminal region (amino-acids 18-217) and a peroxidase-labelled mouse anti-rabbit detection system. As control we used the signals obtained using polyclonal antibodies raised against the β-subunit of the mitochondrial ATPase. The amount of OCRL1 present in each sample was determined by quantitative western blot analysis using a ChemiDoc XRS apparatus and the Quantity One  software (BioRad, Hercules, CA, USA), after correction of protein loading by Coomassie blue staining.
Results
Mutation analysis
We have identified a mutation in the OCRL1 gene in 130 out of the 175 families included for Lowe's syndrome and in 6 out of the 41 Dent disease families. 51 of these mutations were novel ( Table 1) with four of them identified in patients affected by Dent-2 disease. Extensive genomic and cDNA sequencing analysis led to the correction of boundaries of exons 8, 9, 11, 12, 13, 14 in reference to those reported in the Lowe Syndrome Mutation Database 28 and to the use of a cDNA numbering based on the use of initiation codon in exon 1 ( Supplementary Table S1 ).
Near to 200 mutations have been identified so far in the OCRL1 gene in association with Lowe syndrome or Dent-2 disease ( Supplementary Table S2 ). Frameshift, splicing or non-sense mutations leading to a premature termination of the protein represented 63% of the mutations whereas missense mutations and genomic deletion accounted respectively for 33% and 4% of the molecular variations. No noticeable differences in this distribution were noticed when comparing Lowe syndrome or Dent-2 Disease. 33 recurrent mutations were identified and accounted for the disease in 41% of the genotyped families. 17 mutations have been Table S2 , none of these mutations appeared to be population specific.
Genetic investigation of 98 mothers of patients affected by Lowe syndrome showed the occurrence of a de novo mutation in 36 cases (37.2 %) whereas 3 cases of mosaicism were characterized in our panel of genotyped families indicating that, although not frequent, mosaicism must be taken in account for genetic counselling.
As shown in Figure 1 , 53 out of the 66 missense mutations reported to date mapped to the PI(4,5)P 2 phosphatase domain spanning exons 9-15. They involved amino-acids defined as major determinants for specificity of the inositol polyphosphate 5-phosphatase activity [Whisstock et al., 2000; Tsujishita et al., 2001] . The remaining missense mutations were identified in the C-terminal ASH-RhoGAP-like domain spanning exons 16 to 23 [Peck et al., 2002; Faucherre et al., 2003 , Choudhury et al., 2005 Hyvola et al., 2006; Erdmann et al., 2007] and involved amino acids located in well conserved domains (supplementary Figure   S1 ). Noticeably, no missense mutations have been identified so far in exons 1 to 8.
Frameshift mutations or nonsense mutations leading to premature termination of the protein have been characterized in all exons but exons 2 and 3 ( Fig 1) . [Kawano et al., 1998; Monnier et al., 2000] led thus primarily to a premature termination of the protein.
Noticeably, while frameshift and nonsense mutations associated with Lowe syndrome concentrated in exons exons 8 to 23, all frameshift and nonsense mutations causative of Dent 2 disease have been characterized so far only in the first seven exons.
Functional expression of mutations mRNA expression
As shown in Figure mutation resulted in the production of two abnormal transcripts. Sequencing analysis showed that whereas both transcripts could be amplified and quantified, they both lacked the 3' end of exon 1 that contains the ATG initiation codon (supplementary Fig S2) . PI (4,5)P 2 phosphatase activity was measured in 12 patients harbouring a missense mutation and in 11 patients harbouring a nonsense or a frameshift mutation that led to a premature termination of the protein. As presented in table 2 the enzymatic activities measured in patients with either a missense mutation or a mutation leading to a premature termination of the protein showed a mean inhibition of 85-90% when compared to PI (4,5)P 2 phosphatase activity determined in fibroblasts originating either from healthy individuals or from patients addressed for a suspicion of Lowe syndrome and for whom no mutation had been identified in the OCRL1 gene. No significant differences between the residual activities measured in fibroblasts harbouring a missense mutation and those harbouring a nonsense or frameshift mutation were evidenced. Likewise no differences of PI (4,5)P 2 phosphatase activities could be evidenced between Lowe syndrome or Dent-2 patients (not shown).
PIP2ase activity
Residual activities measured in mutant fibroblasts were likely to correspond to non specific hydrolysis of PI (4,5)P 2 by other inositol polyphosphate phosphatases present in fibroblasts since they were also determined in cells fully devoid of OCRL1 as a consequence of a genomic deletion of the OCRL1 gene [Lin et al., 1997; Monnier et al., 2000; this paper] .
OCRL1 protein analysis
The amount of OCRL1 was estimated in total cell extracts using either the total protein amount or the β-ATPase signals for normalisation. As shown in Figure 4 , patients harbouring a missense mutation in the OCRL1 gene (lanes 2-6) had a markedly reduced content of OCRL1 when compared to controls (lanes 1, 7, 8, 12) . Two bands were revealed by antibodies, the upper band at ≈ 105 kDa corresponds to the native OCRL1 while the lower band at ≈ 75 kDa corresponds to a proteolytic product [Lichter-Konecki et al., 2006] . As expected, cells harbouring stop and frameshift mutations and characterized by a low mRNA content showed an almost complete absence of OCRL1 (lanes 9,10,11). For quantification 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Clinical expression of mutations
All but two of the 124 male patients that presented with classical features of the disease i.e. congenital bilateral cataract, central nervous system symptoms and kidney troubles harboured a mutation in the OCRL1 gene. However as no cDNA analysis could be performed for these two patients, we cannot exclude the presence of a mutation not detected by genomic sequencing. At contrast, no mutation in the OCRL1 gene was identified in the 36 additional male patients presenting with an incomplete panel of oculocerebrorenal symptoms although highly suggestive of Lowe syndrome. When tested PI(4,5)P 2 phosphatase activity also excluded the diagnosis of Lowe syndrome in these patients.
6 out of the 41 patients included on the basis of diagnosis of a Dent disease not associated to the CLC5 gene carried a mutation of the OCRL1 gene. None of these 6 patients had ocular or CNS symptoms.
A few mutations that mapped to the same amino acid or to amino acids located at close vicinity were identified in patients addressed either for diagnosis of Lowe syndrome or Dent disease (Table 4 ). The p.Ile274Thr initially described in a patient presenting with the 
CONCLUSIONS AND DISCUSSION
A major consequence of mutations affecting the OCRL1 gene was the loss of PI(4,5)P 2 ase activity regardless of the Lowe or Dent-2 clinical phenotypes associated with mutations in patients and regardless of the pathogenic mechanisms.
Nonsense mutations, genomic deletions, frameshift or splicing mutations leading to the occurrence of a premature termination codon represent 2/3 of the OCRL1 mutations identified to date. Expression studies of these mutations indicated that all but one of the mutations tested resulted in an almost complete absence of mRNA and protein ( Fig. 2 and table 3).
Interestingly, the splicing c.40-14G>A mutation allowed an apparently normal quantitative production of mRNA. However and as shown in Fig. 3 The decrease of the PI(4,5)P 2 ase activity in mutant cells harbouring a missense mutation was usually associated with a deleterious effect of the missense mutations on phosphatase activity, whether they mapped to the catalytic PI(4,5)P 2 ase domain or to the Rho-GAP domain [Lin et al., 1997 ., Hyvola et al., 2006 ., Schrimpton et al., 2009 . However and as illustrated in Fig. 4 and Table 3 , the consequence of missense mutations is mostly a decrease of the amount of OCRL1 present in the cell. This is likely to result from an abnormal processing of the protein since OCRL1 mRNA levels were normal in the cells harbouring these missense mutations (Fig. 2) . The protein degradation might be the consequence of the activation of endoplasmic reticulum-associated degradation (ERAD) or of tunfolded protein response (UPR) as an answer to the accumulation of unfolded or misfolded mutant OCRL1 in the endoplasmic reticulum [Schröder and Kaufman., 2005] . Conclusions of functional studies based on expression mutant OCRL1 in cellular models must thus take in account protein degradation processes when analysing the physiological relevance of the different mutations.
(panel A) the mutation led
Nevertheless, a small amount (20-30%) of OCRL1 was detected in a few mutant cells although PI(4,5)P 2 ase activity was almost totally absent. In these situations, the overall decrease of PI(4,5)P 2 ase activity is likely to result from two processes: a decrease of the amount of OCRL1 through protein degradation and a catalytic inactivation. A few missense mutations e.g. p.Phe242Ser, p.Ala797Pro resulted in the presence of both a small amount of protein and a residual PiP 2 ase activity. Noticeably, although the Lowe patients harbouring these mutations presented with classical eye and kidney features, their neurological symptoms were less severe and their degree of mental retardation was moderate. This may reflect a differential dependence of tissues or of developmental stages toward PI(4,5)P 2 homeostasis.
Differences in clinical expression that were observed between patients harbouring different mutations might thus reflect variability in protein synthesis and/or catalytic properties in the different tissues depending on the nature of the mutation beside variability of the individual genetic background.
Mutations of the OCRL1 gene have been associated with two distinct clinical phenotypes i.e. Lowe syndrome and Dent disease. Although apparently undistinguishable from the Dent phenotype associated to the CLCN5 gene, Dent phenotype associated with OCRL1 mutations has been referred as Dent-2 disease to specify the genetic cause of the The report of truncated forms of OCRL1 that might result from the use of alternative initiation codons open also new perspectives to explain clinical variability associated with OCRL1 mutations. However these investigations were performed on skin fibroblasts and using antibodies that may not recognize all forms of truncated or alternatively spliced OCRL1. It will be very important to extend these studies to other cell types that are more affected by the disease e.g. renal and ocular cells and to use a larger panel of antibodies directed against different domains of the protein in order to gain new insights regarding the differential pathological mechanisms leading to the different clinical phenotypes.
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